NASDAQ:KLDO - Kaleido Biosciences Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $8.90
  • Forecasted Upside: 14,514.12 %
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.06
+0 (0.00%)

This chart shows the closing price for KLDO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kaleido Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KLDO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KLDO

Analyst Price Target is $8.90
▲ +14,514.12% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Kaleido Biosciences in the last 3 months. The average price target is $8.90, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 14,514.12% upside from the last price of $0.06.

This chart shows the closing price for KLDO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in Kaleido Biosciences. This rating has held steady since December 2020, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 2 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 2 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 2 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 2 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2022Chardan CapitalDowngradeBuy ➝ Neutral$3.00 ➝ $1.70High
1/31/2022Chardan CapitalLower Price TargetBuy$11.00 ➝ $3.00High
11/12/2021Chardan CapitalLower Price TargetBuy$15.00 ➝ $11.00Low
11/3/2021JMP SecuritiesLower Price TargetMarket Outperform$25.00 ➝ $22.00High
10/19/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$3.00High
10/8/2021JMP SecuritiesReiterated RatingBuy$25.00Low
7/9/2021Chardan CapitalInitiated CoverageBuy$15.00High
7/1/2021Chardan CapitalReiterated RatingBuyLow
3/8/2021Morgan StanleyLower Price TargetEqual Weight$13.00 ➝ $12.00High
2/9/2021Piper SandlerInitiated CoverageOverweight$19.00Low
1/19/2021Morgan StanleyBoost Price TargetEqual Weight$8.00 ➝ $13.00Medium
1/14/2021Chardan CapitalBoost Price TargetPositive ➝ Buy$10.00 ➝ $17.50Medium
12/23/2020JMP SecuritiesInitiated CoverageOutperform$22.00N/A
10/14/2020JPMorgan Chase & Co.Initiated CoverageUnderweightHigh
8/10/2020Morgan StanleyBoost Price TargetEqual Weight$7.00 ➝ $8.00High
7/15/2020Morgan StanleyLower Price TargetEqual Weight$8.00 ➝ $7.00Medium
5/21/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$8.00Medium
9/19/2019Chardan CapitalReiterated RatingBuyMedium
4/23/2019Chardan CapitalInitiated CoverageBuy ➝ Buy$17.50Low
3/25/2019Morgan StanleyInitiated CoverageOverweight ➝ Overweight$17.00Medium
3/25/2019JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$15.00Medium
3/25/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$20.00Medium
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/6/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/5/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/7/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/5/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

Kaleido Biosciences logo
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $0.06
Low: $0.06
High: $0.07

50 Day Range

MA: $0.07
Low: $0.05
High: $0.09

52 Week Range

Now: $0.06
Low: $0.04
High: $0.14

Volume

49,387 shs

Average Volume

589,939 shs

Market Capitalization

$2.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Kaleido Biosciences?

The following Wall Street research analysts have issued reports on Kaleido Biosciences in the last twelve months: Chardan Capital, JMP Securities, and Morgan Stanley.
View the latest analyst ratings for KLDO.

What is the current price target for Kaleido Biosciences?

0 Wall Street analysts have set twelve-month price targets for Kaleido Biosciences in the last year. Their average twelve-month price target is $8.90, suggesting a possible upside of 14,514.1%.
View the latest price targets for KLDO.

What is the current consensus analyst rating for Kaleido Biosciences?

Kaleido Biosciences currently has 1 sell rating, 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in KLDO, but not buy more shares or sell existing shares.
View the latest ratings for KLDO.

How do I contact Kaleido Biosciences' investor relations team?

The company's listed phone number is (617) 674-9000. The official website for Kaleido Biosciences is www.kaleido.com. Learn More about contacing Kaleido Biosciences investor relations.